BUZZ-Tandem Diabetes Care touches one-year low after brokerages cut PTs

Updates

Shares of medical device maker Tandem Diabetes Care TNDM.O down 32% at $22.85, their lowest level in one year

At least 3 brokerages cut PTs for the co, while maintaining "buy" or equivalent rating

Co late on Wednesday forecast 2025 sales between $997 mln and $1.007 bln vs analysts' estimate of $1.004 billion - data compiled by LSEG

TNDM also projected Q1 sales to be between $219 million and $224 million vs estimate of $220.3 million

"What will likely cause investor consternation is the lower-than-anticipated Q1 2025 revenue guidance and the implied ramp through the rest of the year" - Brokerage Citi

The 2025 outlook reflects the seasonal trends extending into Q1 - RBC Capital analysts

TNDM has risen 16.4% in the last 12 months